Standardized single-platform assay for human monocyte subpopulations: Lower CD14+CD16++ monocytes in females

113Citations
Citations of this article
128Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We present a novel single-platform assay for determination of the absolute number of human blood monocyte subpopulations, i.e., the CD14++ CD16- and the CD14+CD16++ monocytes. A four-color combination of antibodies to CD14, CD16, CD45, and HLA-DR reduces the spill-over of natural killer cells and of granulocytes into the CD14 +CD16++ monocyte gate. For these CD14+CD16 ++ monocytes, the intra-assay coefficient of variation (CV) was 4.1% and the inter-assay CV was 8.5%. Looking at a cohort of 40 donors aged 18-60 years, we found no age dependence. There was however an effect of gender in that females had lower CD14+CD16++ monocytes (45.4 ± 13.5 cells/il) compared with males (59.1 ± 20.3 cells/il) (P < 0.02). Using this novel approach, we can confirm that exercise will lead to more than three-fold increase of the CD14+CD16++ monocytes. Also, we show that therapy with low doses of gluco- corticoids will deplete these cells. This robust single-platform assay may be a useful tool for monitoring the absolute number of monocyte subpopulations in health and disease. © 2010 International Society for Advancement of Cytometry.

Cite

CITATION STYLE

APA

Heimbeck, I., Hofer, T. P. J., Eder, C., Wright, A. K., Frankenberger, M., Marei, A., … Ziegler-Heitbrock, L. (2010). Standardized single-platform assay for human monocyte subpopulations: Lower CD14+CD16++ monocytes in females. Cytometry Part A, 77(9), 823–830. https://doi.org/10.1002/cyto.a.20942

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free